Dabigatran
targets F2 via inhibition
Trials 74 · started per year
Also used as a comparator or background therapy in 38 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06615596 Comparator | Aug 2025 → Jan 2029 expected | atrial fibrillation | China National Center for Cardiovascular Diseases | Recruiting | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05491460 Comparator | Jul 2022 → Dec 2023 | — | Doasense GmbH | Unknown | No outcome recorded |
| Phase 1 | NCT05064800 Comparator | Sep → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03752294 Comparator | May 2019 → May 2022 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | University of Rhode Island | Withdrawn | No outcome recorded |
| Phase 1 | NCT02028780 Background | Jan → Aug 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01688830 Background | Sep 2012 → Nov 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01385683 Comparator | Jun → Dec 2011 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04002011 Comparator | Mar 2022 → Jan 2023 | bleeding disorder, vascular-type | Laval University | Withdrawn | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06322953 Comparator | Mar 2025 → Dec 2027 expected | traumatic brain injury | Walton Centre NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 3 | NCT04284839 Comparator | Jul 2021 → Jun 2027 expected | — | Population Health Research Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT02313584 Comparator | Dec 2014 → Sep 2016 | paroxysmal atrial fibrillation, thrombotic disease | Korea University | Unknown | No outcome recorded |
| Phase 3 | NCT01431456 Comparator | Sep 2013 → Oct 2014 | venous thromboembolism | Martini Hospital Groningen | Completed | No outcome recorded |
| Phase 3 | NCT00262600 Comparator | Dec 2005 → Apr 2009 | atrial fibrillation, stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07352358 Background | Jan 2026 → Jul 2028 expected | cerebral sinovenous thrombosis | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 4 | NCT06212674 Comparator | Oct 2025 → Oct 2027 expected | atrial fibrillation, ischemic stroke | Medical University of Silesia | Recruiting | No outcome recorded |
| Phase 4 | NCT04688723 Comparator | Dec 2020 → Dec 2022 | atrial fibrillation, coronary artery disorder, myocardial infarction, myocardial ischemia | Zuyderland Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04437303 Comparator | Nov 2020 → Mar 2024 | aortic valve stenosis, hemorrhagic disease, myocardial infarction, stroke disorder +2 | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03568890 Comparator | Sep 2018 → Aug 2025 overdue | hemorrhagic disease, thrombotic disease, transient ischemic attack | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03463317 Comparator | Feb 2018 → Nov 2024 | atrial fibrillation | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02606552 Comparator | Jul 2016 → Jun 2017 | atrial fibrillation, coronary artery disorder | Yonsei University | Terminated | No outcome recorded |
| Phase 4 | NCT02723981 Background | Apr 2016 → May 2018 | ST-elevation myocardial infarction, intermediate coronary syndrome | IHF GmbH - Institut für Herzinfarktforschung | Withdrawn | No outcome recorded |
| Phase 4 | NCT02701062 Background | Feb 2016 → Apr 2019 | atrial fibrillation | AtriCure, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02935855 Comparator | Sep 2015 → Apr 2019 | diabetes mellitus | University of Pavia | Completed | No outcome recorded |
| Phase 4 | NCT01994265 Comparator | Nov 2014 → Mar 2021 | atrial fibrillation | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01962545 Background | Nov 2013 → May 2017 | atrial fibrillation, coronary artery disorder | Satoshi Shizuta | Completed | No outcome recorded |
| Phase 4 | NCT02331602 Comparator | Jul 2013 → Oct 2015 | atrial fibrillation | Yokohama City University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01812200 Comparator | Oct 2012 → May 2013 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01478282 Comparator | Jan → Dec 2012 | hemorrhagic disease, hyperheparinemia, thrombotic disease | Gines Escolar | Unknown | No outcome recorded |
| Phase 4 | NCT01468155 Comparator | Jul 2011 → Jan 2017 | atrial fibrillation | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07497893 Background | Dec 2026 → Nov 2029 expected | atrial fibrillation | Ewha Womans University Mokdong Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04684212 Comparator | Jun 2024 | atrial fibrillation, stroke disorder | Brian O'Neill MD | Withdrawn | No outcome recorded |
| — | NCT06058130 Comparator | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05472766 Comparator | Nov 2022 → Mar 2024 | atrial fibrillation | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| — | NCT06449469 Background | May 2021 → Apr 2026 overdue | aortic valve stenosis | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT03465735 Background | Jan 2017 → Aug 2019 | venous thromboembolism | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT02744092 Comparator | Dec 2016 → Oct 2020 | cancer, pulmonary embolism, thrombotic disease, venous thromboembolism | Alliance Foundation Trials, LLC. | Completed | No outcome recorded |
| — | NCT01999179 Background | Jun 2014 → Apr 2019 | neoplasm, venous thromboembolism | Medical College of Wisconsin | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 114 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dabigatran | “For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular...” NCT04437303 ↗108“Patients will be chronically treated with NOAC including apixaban (2x5 mg or 2x2.5 mg depending on the dose reduction regimen) or dabigatran (2x150 mg or 2x110 mg depending on...” NCT06212674 ↗ “DOACs (eg Apixaban, dabigatran, edoxaban and rivaroxaban) are recommended by The National Institute for Health and Care Excellence (NICE) for those over 65 with AF and a...” NCT06322953 ↗ “NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice...” NCT01962545 ↗ “edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or...” NCT03968393 ↗ “For those randomized to group B (NOAC group), patients will be treated using a registered NOAC (rivaroxaban, apixaban or dabigatran, but preferentionally apixaban) at the dose...” NCT02426944 ↗ “Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.” NCT07497893 ↗ “Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles.” NCT06615596 ↗ “Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation.” NCT02606552 ↗ “DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care” NCT05825573 ↗ “Administration of approved DOACs (e.g., apixaban, rivaroxaban, edoxaban, or dabigatran) at standard stroke prevention dosages.” NCT07609654 ↗ “Healthy male and female subjects will will be enrolled to assess the effects on a single dose of dabigatran mesylate (DAB).” NCT04092725 ↗ “Low-molecular-weight heparin bridging to warfarin 3 mg/day, rivaroxaban 10-20 mg/day or dabigatran 110-150 mg twice daily.” NCT07352358 ↗ “Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation.” NCT02998905 ↗ “Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)” NCT03234114 ↗ “Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.” NCT03642509 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “Rivaroxaban 20mg once daily or 15mg once daily / Dabigatran 110mg twice daily or 150mg twice daily” NCT06058130 ↗ “Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)” NCT05387954 ↗ “dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible” NCT01911624 ↗ “choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice” NCT04700826 ↗ “Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP” NCT05472766 ↗ “any approved direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran)” NCT04045665 ↗ “direct oral anticoagulant treatment (apixaban, rivaroxaban, dabigatran, or edoxaban)” NCT01999179 ↗ “Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.” NCT06057467 ↗ “* dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution” NCT04764851 ↗ “Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban” NCT06401616 ↗ “Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)” NCT05006287 ↗ “New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban” NCT02701062 ↗ “dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam” NCT05334108 ↗ “warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban” NCT03062319 ↗ “aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid” NCT03415386 ↗ “dabigatran, apixaban, edoxaban, rivaroxaban” NCT03759938 ↗ “Apixaban Dabigatran Edoxaban Rivaroxaban” NCT05292846 ↗ “Dabigatran (Pradaxa)” NCT07011095 ↗ “Dabigatran (Pradaxa)” NCT03465735 ↗ “Dabigatran (Pradaxa)” NCT01706146 ↗ “Dabigatran” NCT02666742 ↗ |
| Known as | BIBR 953 ZW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02170584 ↗ |
| Known as | Dabigatran (Pradaxa) | “Dabigatran (Pradaxa)” NCT07011095 ↗ |
| Known as | dabigatran etexilate | “Dabigatran etexilate is a novel oral anticoagulant.” NCT02524210 ↗1“multiple doses of Dabigatran Etexilate (150 mg Bid)” NCT02171598 ↗ |
| Known as | dabigatran etexilate mesylate | “dabigatran etexilate mesylate (EM) absorption” PMID 27717999 ↗ Oct 2016 |
| Known as | Dabigatrana | “Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.” NCT03181386 ↗ |
| Known as | Dabigatranetexilat | “Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1).” NCT06449469 ↗ |
| Known as | Pradax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00868179 ↗ |
| Known as | Pradax dabigatran etexilate | “Pradax dabigatran etexilate” NCT00868179 ↗ |
| Known as | Pradaxa | “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗4“Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation.” NCT02606552 ↗ “Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)” NCT03148457 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “Dabigatran (Pradaxa)75 mg” NCT01385683 ↗ |
| Known as | Pradaxa is the brand name for dabigatran | “Pradaxa is the brand name for dabigatran” NCT01478282 ↗ |
| Action | Inhibit | “Dabigatran is a new oral direct thrombin inhibitor.” PMID 19717844 ↗ Aug 2009 |
| Route | Oral | “Dabigatran is a new oral direct thrombin inhibitor.” PMID 19717844 ↗ Aug 2009 |
| Target | F2 | “the direct thrombin inhibitor dabigatran” NCT01812200 ↗ |